Published in Cancer on March 01, 2010
Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol (2013) 6.56
The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. Eur J Nucl Med Mol Imaging (2013) 2.25
Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012. Geburtshilfe Frauenheilkd (2013) 1.14
Optimising Breast Conservation Treatment for Multifocal and Multicentric Breast Cancer: A Worthwhile Endeavour? World J Surg (2016) 1.04
Short course radiotherapy with simultaneous integrated boost for stage I-II breast cancer, early toxicities of a randomized clinical trial. Radiat Oncol (2012) 0.97
Health-related quality of life in survivors of stage I-II breast cancer: randomized trial of post-operative conventional radiotherapy and hypofractionated tomotherapy. BMC Cancer (2012) 0.91
CYP19 genetic polymorphism haplotype AASA is associated with a poor prognosis in premenopausal women with lymph node-negative, hormone receptor-positive breast cancer. Biomed Res Int (2013) 0.87
Optimal sequence of implied modalities in the adjuvant setting of breast cancer treatment: an update on issues to consider. Oncologist (2010) 0.83
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. J Cancer Res Clin Oncol (2012) 0.82
Utilization of neoadjuvant chemotherapy varies in the treatment of women with invasive breast cancer. PLoS One (2013) 0.80
Intraoperative Ultrasound Guidance in Breast-Conserving Surgery Improves Cosmetic Outcomes and Patient Satisfaction: Results of a Multicenter Randomized Controlled Trial (COBALT). Ann Surg Oncol (2016) 0.79
Current status of ultrasound-guided surgery in the treatment of breast cancer. World J Clin Oncol (2016) 0.78
Breast reconstruction following prophylactic or therapeutic mastectomy for breast cancer: Recommendations from an evidence-based provincial guideline. Plast Surg (Oakv) (2014) 0.77
Tissue-simulating phantoms for assessing potential near-infrared fluorescence imaging applications in breast cancer surgery. J Vis Exp (2014) 0.76
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer. J Cancer Res Clin Oncol (2013) 0.76
Three-dimensional quantitative ultrasound for detecting lymph node metastases. J Surg Res (2013) 0.75
Assessment of knowledge of cancer and lymphoedema among breast cancer survivors. Prz Menopauzalny (2014) 0.75
Understanding the factors associated with the surgical management of early breast cancer. Gland Surg (2013) 0.75
Reoperation Rates in Ductal Carcinoma In Situ vs Invasive Breast Cancer After Wire-Guided Breast-Conserving Surgery. JAMA Surg (2017) 0.75
Must breast care delivery models from resource-rich environments be applied to resource-limited environments? World J Surg (2010) 0.75
Surgical margin reporting in breast conserving surgery: Does compliance with guidelines affect re-excision and mastectomy rates? Breast (2015) 0.75
Oncological Outcomes and Complications After Volume Replacement Oncoplastic Breast Conservations-The Glasgow Experience. Breast Cancer (Auckl) (2016) 0.75
Intraoperative Ultrasound in the Treatment of Breast Cancer. Geburtshilfe Frauenheilkd (2013) 0.75
Evaluation of surgical outcomes following oncoplastic breast surgery in early breast cancer and comparison with conventional breast conservation surgery. Med J Armed Forces India (2015) 0.75
Nipple areola complex sparing mastectomy. Gland Surg (2015) 0.75
Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer. Oncotarget (2017) 0.75
Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA (2011) 16.68
Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med (2011) 12.52
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol (2009) 7.21
Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol (2002) 6.51
Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol (2008) 5.28
Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol (2013) 4.28
Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys (2006) 4.22
Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol (2013) 3.92
Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys (2009) 3.91
Patient involvement in surgery treatment decisions for breast cancer. J Clin Oncol (2005) 3.65
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol (2006) 3.52
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51
Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol (2011) 3.45
Local therapy and survival in breast cancer. N Engl J Med (2007) 3.33
Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol (2006) 3.33
Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol (2011) 3.22
Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am (2003) 2.82
Association of routine pretreatment magnetic resonance imaging with time to surgery, mastectomy rate, and margin status. J Am Coll Surg (2009) 2.79
Adoption of intensity-modulated radiation therapy for breast cancer in the United States. J Natl Cancer Inst (2011) 2.77
Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol (2007) 2.76
Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Ann Intern Med (2013) 2.76
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol (2012) 2.72
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res (2010) 2.66
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol (2010) 2.54
Career satisfaction, practice patterns and burnout among surgical oncologists: report on the quality of life of members of the Society of Surgical Oncology. Ann Surg Oncol (2007) 2.50
Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol (2008) 2.43
Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol (2014) 2.38
Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol (2012) 2.38
Ductal lavage findings in women with known breast cancer undergoing mastectomy. J Natl Cancer Inst (2004) 2.37
Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA (2011) 2.28
Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov (2012) 2.23
Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2013) 2.21
Decision involvement and receipt of mastectomy among racially and ethnically diverse breast cancer patients. J Natl Cancer Inst (2009) 2.18
Management of the clinically node-negative axilla: what have we learned from the clinical trials? Oncology (Williston Park) (2014) 2.17
Does aggressive local therapy improve survival in metastatic breast cancer? Surgery (2002) 2.13
Ductal lavage findings in women with mammographic microcalcifications undergoing biopsy. Ann Surg Oncol (2005) 2.13
Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila) (2011) 2.09
Correlates of between-surgeon variation in breast cancer treatments. Med Care (2006) 2.08
Standard for breast conservation therapy in the management of invasive breast carcinoma. CA Cancer J Clin (2002) 2.07
Effective local therapy and long-term survival in breast cancer. Oncology (Williston Park) (2009) 2.06
Breast carcinoma during pregnancy. International recommendations from an expert meeting. Cancer (2006) 2.04
Irradiation in early-stage breast cancer: conventional whole-breast, accelerated partial-breast, and accelerated whole-breast strategies compared. Oncology (Williston Park) (2012) 2.04
Internal mammary nodes in breast cancer: diagnosis and implications for patient management -- a systematic review. J Clin Oncol (2008) 2.04
Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat (2007) 2.01
Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol (2011) 1.99
Should intraoperative frozen section evaluation of breast lumpectomy margins become routine practice? Am J Clin Pathol (2012) 1.99
Beauty and the beast: management of breast cancer after plastic surgery. Ann Surg (2008) 1.98
The Society of Surgical Oncology-American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer: Perspectives for Pathologists. Arch Pathol Lab Med (2014) 1.98
Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol (2009) 1.96
Accelerated partial breast irradiation using brachytherapy for breast cancer: patterns in utilization and guideline concordance. J Natl Cancer Inst (2011) 1.92
Surgical margins in lumpectomy for breast cancer--bigger is not better. N Engl J Med (2012) 1.91
Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer (2012) 1.91
Offering participants results of a clinical trial: sharing results of a negative study. Lancet (2005) 1.90
Measuring quality of life in oncologic breast surgery: a systematic review of patient-reported outcome measures. Breast J (2010) 1.90
An informed decision? Breast cancer patients and their knowledge about treatment. Patient Educ Couns (2006) 1.87
Patterns and correlates of patient referral to surgeons for treatment of breast cancer. J Clin Oncol (2007) 1.84
Axillary dissection can be avoided in the majority of clinically node-negative patients undergoing breast-conserving therapy. Ann Surg Oncol (2013) 1.84
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol (2011) 1.83
International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol (2003) 1.83
Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer (2004) 1.82
Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). J Am Coll Surg (2009) 1.76
Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat (2010) 1.73
Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost. Int J Radiat Oncol Biol Phys (2007) 1.71
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol (2010) 1.71
Preventive therapy for breast cancer: a consensus statement. Lancet Oncol (2011) 1.69
Population-based study of the relationship of treatment and sociodemographics on quality of life for early stage breast cancer. Qual Life Res (2005) 1.67
Breast cancer in the elderly. J Clin Oncol (2007) 1.60
Positive sentinel nodes without axillary dissection: implications for the radiation oncologist. J Clin Oncol (2011) 1.60
Symptom experience and quality of life of women following breast cancer treatment. J Womens Health (Larchmt) (2007) 1.58
Racial and ethnic disparities in the use of postmastectomy breast reconstruction: results from a population- based study. J Clin Oncol (2009) 1.56
Correlates of referral practices of general surgeons to plastic surgeons for mastectomy reconstruction. Cancer (2007) 1.54
Understanding the impact of breast reconstruction on the surgical decision-making process for breast cancer. Cancer (2008) 1.54
Occult malignancy in patients undergoing contralateral prophylactic mastectomy. Ann Surg (2011) 1.53
Patterns and correlates of local therapy for women with ductal carcinoma-in-situ. J Clin Oncol (2005) 1.53
What is an adequate margin for breast-conserving surgery? Surgeon attitudes and correlates. Ann Surg Oncol (2009) 1.52
Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clin Cancer Res (2012) 1.50
Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene (2002) 1.48
Factors associated with patient involvement in surgical treatment decision making for breast cancer. Patient Educ Couns (2006) 1.46
Trastuzumab single-drug therapy after failure of cytotoxic treatment for metastatic breast cancer. Onkologie (2010) 1.45
Case records of the Massachusetts General Hospital. Case 32-2007. A 62-year-old woman with a second breast cancer. N Engl J Med (2007) 1.43
Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. J Clin Oncol (2008) 1.42
A prospective feasibility trial to determine the significance of the sentinel node gradient in breast cancer: a predictor of nodal metastasis location. Cancer (2008) 1.41
ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol (2006) 1.41
Preoperative magnetic resonance imaging in breast cancer: meta-analysis of surgical outcomes. Ann Surg (2013) 1.40
Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer. Ann Surg (2005) 1.39
Variability among breast radiation oncologists in delineation of the postsurgical lumpectomy cavity. Int J Radiat Oncol Biol Phys (2007) 1.37
Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial. PLoS One (2013) 1.34
Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist (2002) 1.33
Presenting features of breast cancer differ by molecular subtype. Ann Surg Oncol (2009) 1.33
Brachytherapy for accelerated partial-breast irradiation: a rapidly emerging technology in breast cancer care. J Clin Oncol (2010) 1.33
Compliance with breast-conservation standards for patients with early-stage breast carcinoma. Cancer (2003) 1.33
Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat (2011) 1.32
Society of Surgical Oncology: position statement on prophylactic mastectomy. Approved by the Society of Surgical Oncology Executive Council, March 2007. Ann Surg Oncol (2007) 1.31